SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2024

Conditions
MaleHemophilia A With InhibitorHemophilia B With InhibitorHemophilia
Interventions
DRUG

SS109

on-demand treatment with SS109 at the time of a new hemorrhage event

Trial Locations (9)

Unknown

Anhui Provincial Hospital, Hefei

The First Affiliated Hospital of Shandong First Medical University, Jinan

The Second Affiliated Hospital of Kunming Medical University, Kunming

Jiangxi Provincial People's Hospital, Nanchang

Yangping Song, Shanxi

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

Xi'an Central Hospital, Xi'an

Affiliated Hospital of Xuzhou Medical University, Xuzhou

Henan Provincial Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Jiangsu Gensciences lnc.

INDUSTRY